{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:51:27Z","timestamp":1790790687496,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejca.2023.03.015","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T03:47:43Z","timestamp":1679543263000},"page":"172-184","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician\u2019s Choice"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Casado","family":"Herraez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro D.","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeline","family":"Colomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Scott","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8836-2633","authenticated-orcid":false,"given":"Sandro","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally E.","family":"Baron-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Laure","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Shapira-Frommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Man","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8429-5744","authenticated-orcid":false,"given":"Mary","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Massaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison Martin","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-1218","authenticated-orcid":false,"given":"Jodi","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimalanand S.","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.03.015_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2019.01440","article-title":"Global, regional, and national burden of endometrial cancer, 1990-2017: results from the Global Burden of Disease study, 2017","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2023.03.015_bib2","first-page":"258","article-title":"Current recommendations and recent progress in endometrial cancer","volume":"69","author":"Brooks","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2023.03.015_bib3","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1002\/cncr.30094","article-title":"Endometrial cancer: not your grandmother's cancer","volume":"122","author":"McAlpine","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.03.015_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.03.015_bib5","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.015_bib6","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.015_bib7","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2023.03.015_bib8","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","article-title":"Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment","volume":"9","author":"Kek\u00e4le","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.ejca.2023.03.015_bib9","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.2147\/CMAR.S191499","article-title":"Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis","volume":"11","author":"Yu","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2023.03.015_bib10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ejca.2023.03.015_bib11","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1097\/IGC.0000000000000245","article-title":"Quality of life research in endometrial cancer: what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic Cancer InterGroup Symptom Benefit Working Group brainstorming session, Leiden 2012","volume":"24","author":"McAlpine","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ejca.2023.03.015_bib12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2023.03.015_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the EuroQol Group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ejca.2023.03.015_bib14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","article-title":"Psychometric properties of the EQ-5D\u20135L: a systematic review of the literature","volume":"30","author":"Feng","year":"2021","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ejca.2023.03.015_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2023.03.015_bib16","article-title":"Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24","volume":"27","author":"Stukan","year":"2018","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10.1016\/j.ejca.2023.03.015_bib17","series-title":"Food and Drug Administration, Oncology Center of Excellence (OCE), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Core patient-reported outcomes in cancer clinical trials","year":"2021"},{"key":"10.1016\/j.ejca.2023.03.015_bib18","first-page":"134","article-title":"Longitudinal data analysis of continuous and discrete responses for pre-post designs","volume":"62","author":"Liang","year":"2000","journal-title":"Sankhy\u0101: The Indian J\u00a0Stat\u00a0Ser\u00a0B"},{"key":"10.1016\/j.ejca.2023.03.015_bib19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(22)00212-1","article-title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2023.03.015_bib20","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.03.015_bib21","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(21)00110-2","article-title":"Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial","volume":"6","author":"Vogel","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.ejca.2023.03.015_bib22","doi-asserted-by":"crossref","first-page":"5523","DOI":"10.2147\/CMAR.S305939","article-title":"Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types","volume":"13","author":"Hofheinz","year":"2021","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.ejca.2023.03.015_bib23","series-title":"(lenvatinib) [prescribing information]","year":"2021"},{"key":"10.1016\/j.ejca.2023.03.015_bib24","series-title":"(pembrolizumab) [prescribing information]","year":"2022"},{"key":"10.1016\/j.ejca.2023.03.015_bib25","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1001\/jama.288.23.3027","article-title":"Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial","volume":"288","author":"Detmar","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2023.03.015_bib26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.03.015_bib27","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology\/GOG0209","volume":"38","author":"Miller","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923001521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:40:37Z","timestamp":1760733637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923001521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":27,"alternative-id":["S0959804923001521"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician\u2019s Choice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}